Compare MHF & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MHF | PLYX |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.5M | 112.7M |
| IPO Year | N/A | 2025 |
| Metric | MHF | PLYX |
|---|---|---|
| Price | $6.42 | $1.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 119.6K | 24.1K |
| Earning Date | 01-01-0001 | 11-14-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | ★ 77.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.84 | $1.76 |
| 52 Week High | $7.22 | $10.93 |
| Indicator | MHF | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 33.92 |
| Support Level | $5.84 | N/A |
| Resistance Level | $7.04 | $2.18 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 54.92 | 13.00 |
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.